Anscheinend verwenden Sie einen älteren Internet Explorer. Leider unterstützen wir, genau wie Microsoft, diesen Browser nicht mehr. Sie werden also Fehlermeldungen und ein inkonsistentes Design erleben.
Bitte haben Sie Verständnis und entschuldigen Sie die Unannehmlichkeiten.
toggle menu

numares further expands its strategic growth in U.S. healthcare sector

numares, based in Regensburg, Germany, is an innovative diagnostics company that applies machine learning to metabolic data to develop analytical tests for high-throughput use in clinical diagnostics and life science research.

In 2018, numares and Mayo Clinic Laboratories have entered into a collaboration to develop clinical diagnostic tests that will measure clusters of risk factors as opposed to individual biomarkers. Mayo Clinic Laboratories provides advanced laboratory testing and pathology services to support 4,000 healthcare organizations around the world.

The diagnostic tests will use nuclear magnetic resonance (NMR) technology, addressing unmet medical needs in cardiovascular and kidney diseases (transplant rejection and precise measurement of kidney function) as well as liver cancer. “The approach of identifying ‘constellations’ of metabolites for diagnostics will play an important role in the future of precision medicine,” says Allan Jaffe, M.D., Division Chair for Clinical Core Laboratory Services in the Department of Laboratory Medicine and Pathology at Mayo Clinic.

In July this year, numares appointed Kathy L. Bates as a new member of the Supervisory Board. Ms. Bates also acts as Senior Director, Laboratory Services and Partnership Development at Mayo Clinic. “We are delighted to welcome Kathy to the board,” says Dr. Volker Pfahlert, Chief Executive Officer of numares. “As we continue our focus on North American expansion, her depth of knowledge and relevant experience in the US healthcare will be invaluable to numares.”